Investigational LEO Pharma IL-22 Receptor Improves EASI Scores in AD
Late-breaking positive phase 2a results were presented at AAD 2023.
POLL: What Topics Did You Most Enjoy at AAD 2023?
Click here to answer this week's poll.
Highlights from AAD 2023
More than 300 innovative sessions, an engaging exhibit hall, and heartfelt networking—there was a lot to pack into AAD 2023! Here are the highlights.
Roflumilast Safe and Efficient for Patients with Chronic Plaque Psoriasis
Results from the phase 3 DERMIS-1 and DERMIS-2 trials were presented at the 2023 American Academy of Dermatology Annual Meeting.
AAD 2023 Pearls from Zoe Diana Draelos, MD
New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients
A pediatric dermatologist and pediatric allergist translated guidelines into clinical practice at AAD 2023.
Phase 3 Data for Bimekizumab Shows Well Maintained Response
A pair of phase 3 trials met all primary and secondary endpoints after 48 weeks.
25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study
By week 24 of the phase 3 study, a quarter of participants felt their vitiligo had improved.
Skin Barrier 101: Keep Up with What Your Patients Are Reading
Jack Arbiser, MD, PhD discusses the connection between the skin barrier and anti-aging products.
Oral Ivarmacitinib Demonstrates Significant Atopic Dermatitis Improvement
Results from the phase 3 study were presented at an AAD late-breaking research session.
Annual Meeting Session Highlights Clinical Pearls in Medical Dermatology
A key session at the annual meeting will share practical advice and tools to better support you and your patients.
POLL: What is Your Current Approach to Peanut Allergies in Your Atopic Dermatitis Patients?
This question drummed up discussion during one AAD 2023 session on the topic. We want to hear from you!
Tips to Organize the Digital Chaos with Alina Bridges, DO
In a world where she practices dermatology, conducts research, and is a super mom, Alina Bridges, DO has nailed down a strategy to not let emails stress her out.
Berdamizer Gel Safe, Well-Tolerated in Patients With Molluscum Contagiosum
The treatment was deemed effective following a phase 3 study.
Expert Tips on Alopecia Management From AAD 2023
Ronda Farah, MD, FAAD, shares her tips and tricks for treating varying types of alopecia.
Treating the Chest with Care on a Transgender Patient
A review on breast cancer screenings and procedures on the chest is essential to ensure proper gender-affirming care.
Treating Body Dysmorphic Disorder in Cosmetic Patients
Patients with common psychocutaneous diseases, including body dysmorphic disorder (BDD), often refuse a psychiatric referral and instead, present to dermatologists and cosmetic surgeons.
Isotretinoin Best Practices: New Formulations, Avoiding Relapses, and More
Joshua Zeichner, MD, delivered a boot camp on isotretinoin use at AAD 2023, including an overview of newer formulations of the acne drug that could help counter the common absorption challenges.
Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response
What can you do when a medication for psoriasis yields a suboptimal response? New data presented at the 2023 AAD Annual Meeting provides valuable insight on next steps for treatment.
Raj Chovatiya, MD, PhD, Discusses All Things Inflammatory Diseases at AAD 2023
With the recent therapeutic revolution, there has never been a better time to find the right treatment option for your patient suffering from inflammatory diseases.
